These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 16645323)
1. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Ziras N; Potamianou A; Varthalitis I; Syrigos K; Tsousis S; Boukovinas I; Tselepatiotis E; Christofillakis C; Georgoulias V Oncology; 2006; 70(2):106-14. PubMed ID: 16645323 [TBL] [Abstract][Full Text] [Related]
2. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L Oncology; 2004; 66(5):371-8. PubMed ID: 15331924 [TBL] [Abstract][Full Text] [Related]
4. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556 [TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562 [TBL] [Abstract][Full Text] [Related]
6. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415 [TBL] [Abstract][Full Text] [Related]
8. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627 [TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G Oncology; 2005; 69(1):27-34. PubMed ID: 16088232 [TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Kouroussis C; Souglakos J; Mavroudis D; Papadouris S; Kakolyris S; Agelaki S; Kalbakis K; Panopoulos C; Vardakis N; Sarra E; Georgoulias V Am J Clin Oncol; 2002 Dec; 25(6):627-31. PubMed ID: 12478014 [TBL] [Abstract][Full Text] [Related]
11. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
12. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304 [TBL] [Abstract][Full Text] [Related]
13. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265 [TBL] [Abstract][Full Text] [Related]
15. Current status of capecitabine in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635 [TBL] [Abstract][Full Text] [Related]
16. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626 [TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458 [TBL] [Abstract][Full Text] [Related]
18. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151 [TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748 [TBL] [Abstract][Full Text] [Related]
20. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]